Depomed Reports Second Quarter 2010 Financial Results

Depomed Reports Second Quarter 2010 Financial Results
MENLO PARK, Calif., Aug 5, 2010 (GlobeNewswire via COMTEX) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the second quarter ended June 30, 2010.


Net income for the three months ended June 30, 2010 was $4.1 million, or $0.08 per share compared to a net loss for the three months ended June 30, 2009 of $9.6 million, or $0.19 per share. The receipt and recognition of the $10.0 million milestone payment from Abbott Products Inc. related to the FDA's acceptance for review of the New Drug Application for DM-1796 for the treatment of post-herpetic neuralgia resulted in the three months ended June 30, 2010 being a profitable quarter. The results for the three months ended June 30, 2010 also include a total of $2.4 million in charges associated with the Company's voluntary recall of 52 lots of the 500mg formulation of GLUMETZA(R) (extended release metformin hydrochloride tablets).

Revenue for the three months ended June 30, 2010 was $24.4 million compared to $11.6 million for the three months ended June 30, 2009. The 110% increase in revenue year-over-year was primarily attributable to receipt and recognition of the $10.0 million milestone payment from Abbott Products Inc. and a $3.4 million increase in GLUMETZA product sales.

Operating expenses for the three months ended June 30, 2010 were $17.2 million compared to $20.0 million for the three months ended June 30, 2009. The decrease in operating expenses was primarily attributable to a $5.5 million decrease in research and development expenses resulting from decreased clinical research organization costs associated with the Serada(R) and DM-1796 clinical programs, which was partially offset by a $2.5 million increase in promotion fee expense related to the Company's promotion agreement for GLUMETZA with Santarus, Inc., resulting from increased GLUMETZA product sales. Stock-based compensation expense was $0.5 million for the three months ended June 30, 2010 as compared to $0.7 million for the three months ended June 30, 2009.

Cash, cash equivalents and marketable securities were $76.9 million as of June 30, 2010 compared to $81.8 million as of December 31, 2009.

"We achieved important milestones in the second quarter. The FDA accepted for filing our licensee's New Drug Application for DM-1796 for post-herpetic neuralgia, which triggered a $10 million milestone payment to us. We now look forward to a potential NDA approval milestone of $35 - $60 million in the first quarter of next year. Also, preparations for Serada's Breeze 3 trial progressed well and we expect to begin enrolling patients later this quarter," said Carl A. Pelzel, president and chief executive officer of Depomed.

Second Quarter 2010 Highlights

FDA acceptance for filing of the New Drug Application for investigational post-herpetic neuralgia treatment DM-1796 filed by licensee Abbott Products Inc. (May 2010).
Receipt of $10 million milestone payment from Abbott Products Inc. for DM-1796 (June 2010).
Announced the results of a new clinical study that demonstrated patients with type 2 diabetes may be able to tolerate higher doses of metformin using GLUMETZA (June 2010).
Initiated a voluntary, wholesaler-level recall of 500mg GLUMETZA (metformin hydrochloride extended release) tablets due to the presence of trace amounts of a chemical called 2,4,6-tribromoanisole (TBA) in bottles containing 500mg GLUMETZA tablets. The recall is precautionary and is not due to risks to patient health. No serious events associated with TBA have been documented in the medical literature (June 2010).
Conference Call

Depomed will host a conference call today, Thursday, August 5, beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results. The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate Serada(R) is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform(R) drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, http://www.depomed.com.

The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.

The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to our clinical development programs; our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

                                    DEPOMED, INC.
                         CONDENSED STATEMENTS OF OPERATIONS
                 (in thousands, except share and per share amounts)
                                     (Unaudited)


                                       Three Months Ended     Six Months Ended June
                                            June 30,                  30,
                                     ----------------------  ----------------------

                                        2010        2009        2010        2009
                                     ----------  ----------  ----------  ----------
  Revenues:
   Product sales                        $11,657      $8,408     $24,257     $15,248
   Royalties                                 91         529         179         993

   License and milestone revenue         12,671       2,671      15,342       5,239
                                     ----------  ----------  ----------  ----------
  Total revenues                         24,419      11,608      39,778      21,480

  Costs and expenses:
   Cost of sales                          2,981       1,229       4,462       2,261
   Research and development expense       4,570      10,024       9,758      20,045
   Selling, general and
    administrative expense:
    Promotion fee expense                 8,099       5,640      16,978      10,184
    Other selling, general and
     administrative expense               4,541       4,305       8,091       8,763
                                     ----------  ----------  ----------  ----------
   Total selling, general and
    administrative expense               12,640       9,945      25,069      18,947
                                     ----------  ----------  ----------  ----------

  Total costs and expenses               20,191      21,198      39,289      41,253
                                     ----------  ----------  ----------  ----------

  Income (loss) from operations           4,228     (9,590)         489    (19,773)

  Other income (expense):
   Interest and other income                 56         236         150         550

   Interest expense                       (157)       (263)       (340)       (548)
                                     ----------  ----------  ----------  ----------
  Total other income (expense)            (101)        (27)       (190)           2

  Net income (loss) before income
   taxes                                  4,127     (9,617)         299    (19,771)


  Provision for income taxes                (1)           2         (2)           1
                                     ----------  ----------  ----------  ----------


  Net income (loss)                      $4,126    $(9,615)        $297   $(19,770)
                                     ==========  ==========  ==========  ==========

  Basic net income (loss)
   applicable to common
  stock shareholders per common
   share                                  $0.08     $(0.19)       $0.01     $(0.39)
  Diluted net income (loss)
   applicable to common
  stock shareholders per common
   share                                  $0.08     $(0.19)       $0.01     $(0.39)

  Shares used in computing basic
   net income
  (loss) per common share            52,436,681  51,263,620  52,368,085  51,235,735
  Shares used in computing diluted
   net income
  (loss) per common share            53,103,623  51,263,620  52,918,507  51,235,735

                         DEPOMED, INC.
                   CONDENSED BALANCE SHEETS
             (in thousands, except share amounts)

                                                     December
                                        June 30,       31,

                                          2010         2009
                                       -----------  ---------
                                       (Unaudited)     (1)
                 ASSETS
  Current assets:
   Cash and cash equivalents               $22,245    $26,821
   Marketable securities                    45,097     42,922
   Accounts receivable                       4,461      4,933
   Inventories                               1,476      2,565

   Prepaid and other current assets          1,567      1,185
                                       -----------  ---------
    Total current assets                    74,846     78,426
  Marketable securities, long-term           9,544     12,016
  Property and equipment, net                  741        942

  Other assets                                 197        197
                                       -----------  ---------

                                           $85,328    $91,581
                                       ===========  =========
     LIABILITIES AND SHAREHOLDERS'
                 EQUITY
  Current liabilities:
   Accounts payable and accrued
    liabilities                             14,230     15,222
   Deferred product sales                    1,581      1,635
   Deferred license revenue                 11,132     11,184
   Other current liabilities                   437        414

   Current portion of long-term debt         3,978      3,747
                                       -----------  ---------
    Total current liabilities               31,358     32,202
  Deferred license revenue,
   non-current portion                      36,015     41,306
  Long-term debt, net of current
   portion                                     121      2,170
  Other long-term liabilities                  104        177
  Commitments
  Shareholders' equity:
   Preferred stock, no par value,
    5,000,000 shares authorized;
   Series A convertible preferred
    stock, 25,000 shares designated,
   18,158 shares issued and
    surrendered, and zero shares
   outstanding at June 30, 2010 and
    December 31, 2009                           --         --
   Common stock, no par value,
    100,000,000 shares authorized;
   52,546,064 and 52,200,358 shares
    issued and outstanding at
   June 30, 2010 and December 31,
    2009, respectively                     189,556    187,895
   Accumulated deficit                   (171,906)  (172,202)
   Accumulated other comprehensive
    gain                                        80         33
                                       -----------  ---------

    Total shareholders' equity              17,730     15,726
                                       -----------  ---------

                                           $85,328    $91,581
                                       ===========  =========


  --------------------------------
  (1) Derived from the audited financial statements included
   in the Company's Annual
  Report on Form 10-K for the year ended December 31, 2009.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Depomed, Inc.

CONTACT:
Depomed, Inc.
Sheilah Serradell
650-462-5900
[email protected]
 

.

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.